Shortreed, Susan M. http://orcid.org/0000-0001-7918-601X
Gray, Regan
Akosile, Mary Abisola
Walker, Rod L.
Fuller, Sharon
Temposky, Lisa
Fortmann, Stephen P.
Albertson-Junkans, Ladia
Floyd, James S.
Bayliss, Elizabeth A.
Harrington, Laura B.
Lee, Mi H.
Dublin, Sascha
Funding for this research was provided by:
Kaiser Permanente's Garfield Memorial Fund
Kaiser Permanente Washington Health Research Institute
National Heart, Lung, and Blood Institute (K01HL139997)
Article History
Received: 12 October 2021
Revised: 2 December 2021
Accepted: 3 December 2021
First Online: 24 January 2022
Declarations
:
: Appropriate Institutional Review Boards approved this study.
: Financial Interests: SMS was a co-Investigator on Kaiser Permanente Washington Health Research Institute projects funded by Syneos Health, who is representing a consortium of pharmaceutical companies carrying out studies mandated by the US Federal Drug Administration regarding the safety of extended-release opioids. SPF has a research contract from Pfizer|BioNTech as a site for clinical trials of their SARS-CoV-2 RNA vaccine, which is unrelated to the work reported in this paper. JSF has consulted for Shionogi Inc. LT and SD have received research funding on an unrelated topic from GlaxoSmithKline and SD has received funding from Jazz Pharmaceuticals for unrelated work. Non-financial Interests: none.
: The funders had no role in selecting health systems, study design, data collection, data analysis, data interpretation, or writing up of the results.
Free to read: This content has been made available to all.